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ABSTRACT 
The application of nanomedicines has proved to be effective for the therapy of various types of cancer compared to conventional 
treatments such as chemotherapy and radiation therapy. The nanomedicines can treat various cancers with the precise target 
without affecting the normal cells. In addition, by utilizing of enhanced permeability and retention (EPR) effect, nanomedicines 
can selectively targeting disease site and yield very promising therapeutic results for cancer treatment. Among all available 
nanomedicines, organic materials such as polymers are widely used in recent decades as biomaterials for their favorable properties 
like excellent biocompatibility, easy design and preparation, several types of structures and interesting biomimetic character, 
which warrants the further evaluations on these kinds of innovative material. Inorganic nanoparticles such nanogold also 
demonstrated the ability to target cancer and can be employed as both therapeutic and imaging agents. This mini-review will give a 
brief discussion of using inorganic and organic nanoparticles for the treatment of cancer. 
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Cancer has become one of the most deadly 
diseases due to its fast abnormal cell growth. Change in 
the DNA sequence by mutation and thereby altering the 
genetic expression is the root cause of cancer. This 
mutation could result from several external factors like 
exposure to UV light or other carcinogenic compounds 
like tobacco. DNA methylation occurs because of the 
mutation, in which a methyl group is added to the 
cytosine and adenine of DNA. 
At present, chemotherapy is the most common 
and widely used treatment for cancer
1-4
. 
Nanomedicines, use the latest nanotechnology for many 
medical applications
5-7
. According to Heim & 
Mitelman
8
, nanomedicines have been proven effective 
in treating and preventing cancer compared to other 
forms of treatments
9
. The drugs used in the 
nanomedicines are prepared in nanometers and thus can 
be directed to the site of cancer accurately without 
many side effects
10,11
.      
 CURRENTLY USED METHODS FOR 
TREATING CANCER  
In order to treat cancer effectively, it is quite 
necessary to diagnose cancer at the early stage
12
. Due to 
the relatively immature diagnose technique, it  is hard 
to detect the cancer at an early stage
13
. Fortunately, 
there are multiple potent therapeutic techniques 
available for cancer treatment. 
Surgery is one of the most common 
approaches used for removing the tumor at an early 
stage, which prevents the tumor cells from spreading to 
other normal organs. Chemotherapy, radiation therapy, 
hormonal therapy, and immunotherapy are conventional 
therapies for cancer treatment
14
. During chemotherapy, 
many anti-cancer drugs, such as docetaxel, doxorubicin, 
cyclophosphamide, etc, are administered into the 
human body to inhibit cell proliferation and 
metastasis
15
. Depending on the different characteristics 
of cancer, various drugs are applied to the patients 
during the treatment. This kind of therapy is usually 
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combined with some other form of treatments, such as 
radiation therapy to improve the efficacy. 
The effectiveness of this treatment also 
depends on the type of cancer and what stage of cancer 
has entered
16
. Flygare et al believed that if the treatment 
has been given at an early stage, .cancer would be 
sensitive to many kinds of treatments
17
.  Leukemia, a 
type of cancer occurring in the bone marrow, which 
causes a rise in the number of white blood cells, can be 
treated with chemotherapy with a good outcome. 
However, during the treatment of brain and skin tumors, 
chemotherapy has not been reported to be very 
effective
18
. This may due to the poor permeability of 
Blood- Brain Barrier (BBB) and the of drug resistance 
produced by p-glycoprotein. 
In addition, it is essential to have the “perfect” 
dosage of the drugs that are incorporated into 
chemotherapy
19
. As these drugs are very toxic and 
efficient, overdosage can be very harmful to normal 
organs of cancer suffering patient. While low dosage 
may not even have effects on the cancerous cells and 
tissues. Therefore, it is significant to have this “perfect” 
drug dosage, which highly depends on the stage of 
cancer, body surface area, body mass, height, and age 
of a patient
20
. It has been reported that the 
chemotherapy often related to some side effects without 
the targeting, which will cause damage to other normal 
organs
21
. In most circumstances, patient receiving this 
treatment often suffer from a headache, nausea 
diarrhea, constipation and abdominal pain. Moreover, 
the immune system is usually impaired by this non-
targeting effect shown as the vastly decreasing white 
blood cells. Hair loss is another common side effect 
resulted from the inhibition of hair cells from dividing 
normally. 
Radiation therapy is another technique that can 
be applied to the treatment of cancer. Briefly, the 
cancerous cells are exposed to ionizing radiation that 
can potentially kill those cells. According to Mi
22
, this 
therapy is effective if the cancer is localized to a 
restricted area without metastasis. This therapy causes 
damage to the DNA of the cancerous cells and thereby 
inhibits the cell proliferation.  
Radiation therapy can be painless, which is 
different from chemotherapy. Nevertheless, common 
side effects, such as nausea, damage to the epithelial 
tissues, and infertility, are still presented.  
USEFULNESS OF NANOMEDICINES 
FOR CANCER THERAPY BASED ON 
EPR EFFECT 
The Enhanced Permeability and Retention 
(EPR) effect is a unique property. To be more specific, 
due to the differences of pathophysiological and 
anatomical in solid tumors, nanosize drugs tend to leak 
out of the loose tumor blood vessel easily and 
accumulate in solid tumors
23
. The EPR based cancer 
treatment has become highly effective and offered a 
broad range of potentiality to the patients
24
.      
The side effects are similar to other common 
cancer treatment
25
. According to Cha
26
, the small sizes 
of nanomedicines with targeting ligand facilitate their 
binding to the cancerous cells accurately and thus can 
yield satisfactory result compared to conventional 
treatments. 
The tumor cells have their own characteristics. 
They are able to attract the blood vessels to provide 
nutrition and oxygen, which will boost angiogenesis. In 
addition, tumors have a poor lymphatic drainage system 
that leads to the variable retention rate produced by 
high interstitial pressure. Due to these merits, 
nanomedicines often easily leak out of the blood vessel 
and enter the actual tumor tissues
27
. Eventually, 
because of the high retention rate of the tumor, once the 
tumor tissues have taken up the nanomedicines, it is 
tough to escape from the tumor again
28
.  
USE OF POLYMER NANOPARTICLE 
FOR TREATING CANCER 
In the field of smart drug delivery, polymer 
plays an important role, in its ability to deliver 
therapeutic agents directly to the site of action with 
high efficiency
29,30
. Thus, the delivery system of the 
smart drug has become successful by the application of 
advanced polymer science in the field of 
nanobiotechnology
31,32
. It possesses some valuable 
features, such as sustained and controlled release, 
targeted delivery
33,34
. There are several micro-scale and 




In addition, many polymeric nanoparticle 
delivery systems are used in the therapeutic treatment 
of cancer
39-41
. According to Kim et al
42
, the properties 
of the nanoparticle systems need to be adjusted 
according to the characteristics of the tumor. The types 
of nanoparticle systems explored for applications in 
cancer therapy include the dendrimers, polymers as 
well as the polymeric nanoparticles. The increasing 
number of interests in modifying the polymeric 
chemical systems gives them a direction for the targeted 
and therapeutic aspects
43
. Several polymeric systems 
have been developed into therapeutic platforms, which 
include the solid polymeric nanoparticles and polymeric 
micelle. The function of the nanoparticles was to assist 
achieving the extended circulation time of drug and 
reducing the nonspecific tissue distribution. The 
negatively charged nanoparticles are more efficient than 
the positively charged ones and the size of these 
particles range from 1-100 nm that help to increase the 
phagocytic capability of the cell and thereby enhancing 
the drug delivery system. 
USE OF GOLD NANOPARTICLE FOR 
CANCER THERAPY 
Nanoparticles have been developed as it 
possesses valuable impact on the treatment of various 
diseases
44-46
. It has been reported that gold 
nanoparticles are able to absorb a certain wavelength of 
light and produce greatly increased temperature
47
. This 
is one of the very effective thermal therapies. Due to 
their increased atomic mass, the absorption wavelength 
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can also shift. This is quite different from the soft tissue 
cells that are not able to absorb the extensive amount of 
radiation during the treatment. Thus, as per Hainfeld et 
al stated, an increase in the dose of radiation is possible 
using the gold nanoparticles for treating tumors and 
cancers when gold nanoparticles are heated up
48
.  
In the field of nanotechnology, nanoparticles 
are optimized on their surface, size, zeta and the inner 
phase to treat various types of cancer
49
. With specific 
surface medication, drugs have increased their potential 
in targeting the site of action without causing much side 
effects. As stated by Maeda et al
33
, a 5-nm gold 
nanoparticle has been conjugated to cetuximab 
covalently along with gemcitabine for the treatment of 
pancreatic cancer. In order to decrease the possibility of 
affect normal healthy cells during the treatment, gold 
nanoparticles are usually coated with an antibody that is 
able to recognize specific receptor on target cancer cell. 
According to Alhasan et al
50
, the particle size of PEG-
coated gold nanoparticles around 130 nm in diameter 
are observed to be utilized for treating cancer-based on 
the EPR effect
51
. Effect of gold nanoparticles during 
cancer treatment is evaluated based on the color and 
distance. It is generally believed that gold nanoparticles 
are not toxic, which enhances their use in the various 
treatment processes
52
. Also, gold nanoparticles have 
also been employed as imaging modalities to detect 
cancer cells due to the enhanced scattering ability upon 
absorbing of radiation. Another positive impact of gold 
nanoparticles is by utilizing antibody for Epidermal 
Growth Factor Receptor (EFGR), which is a protein 
that expressed on the surface of cancer cells. This 
facilitates the interaction with cancer cells other than 
the normal cells. It has been reported that gold 
nanoparticles have the ability to heat the cancer cells in 
a rapid manner compared to the normal cells based on 
the property of heat-conductor exhibited by gold
42
. 
Eventually, Gold nanoparticles with cell penetrating 
peptide enhance their ability to be uptake by the cancer 
cells, which will essentially increase their accumulation 
in the tumor based on the EPR effect.  
CONCLUSION 
The application of nanomedicines has proved 
to be effective for cancer treatment compared to 
conventional chemotherapy and radiation therapy. The 
nanomedicines can treat various cancers with the 
precise target without affecting the normal cells. In 
addition, by utilizing of enhanced permeability and 
retention (EPR) effect, nanomedicines can yield a very 
promising result for cancer treatment.   
Moreover, polymers are widely used in recent 
decades as biomaterials for their favorable properties 
like excellent biocompatibility, easy design and 
preparation, several types of structures and interesting 
biomimetic character, which warrants the further 
evaluations on these kinds of innovative materials.  
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